Dalcetrapib seen topping list of Japanese-origin blockbusters
This article was originally published in Scrip
Executive Summary
Japan Tobacco's CETP inhibitor dalcetrapib (JTT-705) has moved to the top of a new list of predicted blockbuster drugs originating in Japan, helped by a global licensing deal with Roche and the discontinuation of Pfizer's same class molecule, torcetrapib, in late 2006.